These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23345305)

  • 41. Phase I oncology trials incorporating patient choice of dose.
    Huson LW
    Br J Cancer; 2012 Sep; 107(7):1022-4. PubMed ID: 22929891
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Principles of dose finding studies in cancer: a comparison of trial designs.
    Jaki T; Clive S; Weir CJ
    Cancer Chemother Pharmacol; 2013 May; 71(5):1107-14. PubMed ID: 23299793
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Some notable properties of the standard oncology Phase I design.
    Hather GJ; Mackey H
    J Biopharm Stat; 2009; 19(3):543-55. PubMed ID: 19384695
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Re: Dose escalation methods in phase I cancer clinical trials.
    Zohar S; O'Quigley J
    J Natl Cancer Inst; 2009 Dec; 101(24):1732-3; author reply 1733-5. PubMed ID: 19893006
    [No Abstract]   [Full Text] [Related]  

  • 45. Multi-institutional phase I trials of anticancer agents.
    Dowlati A; Manda S; Gibbons J; Remick SC; Patrick L; Fu P
    J Clin Oncol; 2008 Apr; 26(12):1926-31. PubMed ID: 18421046
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early phase trial designs and endpoints for targeted therapies in rare genotype subsets.
    Mandrekar SJ
    Am Soc Clin Oncol Educ Book; 2014; ():e107-10. PubMed ID: 24857087
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years.
    van Brummelen EM; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
    J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):235-42. PubMed ID: 26960536
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Isotonic designs for phase I cancer clinical trials with multiple risk groups.
    Yuan Z; Chappell R
    Clin Trials; 2004; 1(6):499-508. PubMed ID: 16279290
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comments on 'A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies'.
    Riviere MK; Zohar S
    Stat Med; 2016 Feb; 35(3):475-8. PubMed ID: 26757957
    [No Abstract]   [Full Text] [Related]  

  • 50. Dose-finding designs: the role of convergence properties.
    Oron AP; Azriel D; Hoff PD
    Int J Biostat; 2011 Oct; 7():Article 39. PubMed ID: 22718676
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alternate designs for conduct and analysis of phase I cancer trials.
    Lévy V; Zohar S; Porcher R; Chevret S
    Blood; 2001 Aug; 98(4):1275-6. PubMed ID: 11510472
    [No Abstract]   [Full Text] [Related]  

  • 52. Reply to M. Voskoboynik et al.
    Hyman DM; Eaton AA; Gounder MM; Ivy SP; Iasonos A; Spriggs DR
    J Clin Oncol; 2014 Oct; 32(28):3199-200. PubMed ID: 25071117
    [No Abstract]   [Full Text] [Related]  

  • 53. A two-stage algorithm for designing phase I cancer clinical trials for two new molecular entities.
    Su Z
    Contemp Clin Trials; 2010 Jan; 31(1):105-7. PubMed ID: 19879974
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Designs for phase I trials in ordered groups.
    Conaway MR; Wages NA
    Stat Med; 2017 Jan; 36(2):254-265. PubMed ID: 27624880
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The changing landscape of phase I trials in oncology.
    Wong KM; Capasso A; Eckhardt SG
    Am Soc Clin Oncol Educ Book; 2015; ():3-8. PubMed ID: 25993134
    [No Abstract]   [Full Text] [Related]  

  • 56. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Practical designs for Phase I combination studies in oncology.
    Wages NA; Ivanova A; Marchenko O
    J Biopharm Stat; 2016; 26(1):150-66. PubMed ID: 26379085
    [TBL] [Abstract][Full Text] [Related]  

  • 58. What skills and training do phase I clinical research nurses need?
    McAdams F
    ONS Connect; 2012 Jul; 27(7):15. PubMed ID: 22855984
    [No Abstract]   [Full Text] [Related]  

  • 59. Estimating the probability of toxicity at the recommended dose following a phase I clinical trial in cancer.
    O'Quigley J
    Biometrics; 1992 Sep; 48(3):853-62. PubMed ID: 1420845
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New designs for phase II trials: application to a trial of targeted therapies vs. chemotherapy in patients age > 60 with AML/high-risk MDS.
    Estey EH
    Ann Hematol; 2004; 83 Suppl 1():S94-6. PubMed ID: 15124692
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.